Iovance Biotherapeutics announces real-world study data on Amtagvi

Iovance Biotherapeutics (IOVA) announced that a real-world, retrospective study demonstrates the benefit of commercial Amtagvi in real-world clinical settings for patients with advanced melanoma previously treated with immune checkpoint inhibitor therapy and, if appropriate, targeted therapy. Among 41 evaluable patients treated at four authorized treatment centers, the physician-assessed objective response rate was 48.8%. Response rates with Amtagvi were higher in third-line or earlier patients with an ORR of 60.9%. An ORR of 33.3% was observed in patients following three or more prior lines of therapy. All evaluable patients received commercial Amtagvi according to the U.S. prescribing information and completed at least one follow-up physician assessment.